-
Support PPMD’s commitment to moving the science further, faster
Greetings from Indiana! I write today letting you know that thanks to a generous pledge […]
-
WATCH: Sevasemten – CANYON Trial Topline Results (Webinar Recording)
Edgewise Therapeutics recently joined PPMD for a breaking news community webinar, during which Edgewise provided […]
-
Your gift to PPMD is a commitment to accelerating progress
As a pediatric neurologist who takes care of children with neuromuscular diseases, I’ve had the […]
-
PPMD Convenes GI, GU, and Swallowing Experts for Two-Day Workshop
Earlier this month, PPMD convened experts from across the country in Columbus, Ohio for a […]
-
Percheron Announces Termination of Phase 2B Study of Avicursen for Duchenne
PPMD is disappointed to learn of Percheron Therapeutics’ recent decision to terminate the company’s ongoing […]
-
There’s never a dull moment living with Duchenne muscular dystrophy
Living with Duchenne muscular dystrophy (DMD) has involved a series of challenges and triumphs, each […]
-
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51
PPMD is disappointed to learn that PepGen Inc. has received a full clinical hold notice […]
-
PepGen’s DMD Exon 51 Skipping Program On Clinical Hold In US
PepGen has received a clinical hold notice from the FDA regarding its Investigational New Drug […]
-
Edgewise Therapeutics Announces Positive Topline Results from CANYON Phase 2 Trial of Sevasemten in Individuals with Becker
Edgewise Therapeutics, Inc., has announced positive topline results from the double-blind, randomized, placebo-controlled Phase 2 […]
-
Edgewise announces Topline results for Becker Phase 2 Trial
As an early funder of Edgewise, CureDuchenne is pleased to share that the Phase 2 […]
